Mammoscintigraphy with Technetium-99m-Sestamibi in Suspected Breast Cancer

Javier Villanueva-Meyer, M. H. Leonard, E. Briscoe, F. Cesani, S. A. Ali, S. Rhoden, M. Hove, D. Cowan

Research output: Contribution to journalArticle

116 Citations (Scopus)

Abstract

Our goal was to determine the clinical usefulness of 99mTc-sestamibi to identify breast cancer in patients prior to biopsy. Methods: We studied 66 patients who received 20 mCi 99mTc-sestamibi intravenously. Lateral and anterior planar images were gathered within 30 min of the injection. Only focal increased uptake was interpreted as positive. Confirmatory pathologic diagnoses were obtained within 2 mo. The prevalence of breast cancer in our sample was 54%. Results: We report an overall sensitivity of 83% and specificity of 93% for the diagnosis of breast cancer. In palpable lesions, the sensitivity was of 94% with a specificity of 91%, while in nonpalpable abnormalities the sensitivity was of 64% with a 100% specificity. Six patients with a malignancy had negative scans, four of these lesions were nonpalpable. Only two of 31 patients with benign lesions had an abnormal scan. Conclusion: Mammoscintigraphy with 99mTc-sestamibi has high specificity and adequate sensitivity for the noninvasive diagnosis of breast carcinomas.

Original languageEnglish
Pages (from-to)926-930
Number of pages5
JournalJournal of Nuclear Medicine
Volume37
Issue number6
StatePublished - 1996

Fingerprint

Technetium Tc 99m Sestamibi
Breast Neoplasms
Sensitivity and Specificity
Biopsy
Injections
Neoplasms

Keywords

  • Breast cancer
  • Technetium-99m-sestamibi

ASJC Scopus subject areas

  • Radiological and Ultrasound Technology

Cite this

Villanueva-Meyer, J., Leonard, M. H., Briscoe, E., Cesani, F., Ali, S. A., Rhoden, S., ... Cowan, D. (1996). Mammoscintigraphy with Technetium-99m-Sestamibi in Suspected Breast Cancer. Journal of Nuclear Medicine, 37(6), 926-930.

Mammoscintigraphy with Technetium-99m-Sestamibi in Suspected Breast Cancer. / Villanueva-Meyer, Javier; Leonard, M. H.; Briscoe, E.; Cesani, F.; Ali, S. A.; Rhoden, S.; Hove, M.; Cowan, D.

In: Journal of Nuclear Medicine, Vol. 37, No. 6, 1996, p. 926-930.

Research output: Contribution to journalArticle

Villanueva-Meyer, J, Leonard, MH, Briscoe, E, Cesani, F, Ali, SA, Rhoden, S, Hove, M & Cowan, D 1996, 'Mammoscintigraphy with Technetium-99m-Sestamibi in Suspected Breast Cancer', Journal of Nuclear Medicine, vol. 37, no. 6, pp. 926-930.
Villanueva-Meyer J, Leonard MH, Briscoe E, Cesani F, Ali SA, Rhoden S et al. Mammoscintigraphy with Technetium-99m-Sestamibi in Suspected Breast Cancer. Journal of Nuclear Medicine. 1996;37(6):926-930.
Villanueva-Meyer, Javier ; Leonard, M. H. ; Briscoe, E. ; Cesani, F. ; Ali, S. A. ; Rhoden, S. ; Hove, M. ; Cowan, D. / Mammoscintigraphy with Technetium-99m-Sestamibi in Suspected Breast Cancer. In: Journal of Nuclear Medicine. 1996 ; Vol. 37, No. 6. pp. 926-930.
@article{1bd2b3b20d56417a86599892d4c2558a,
title = "Mammoscintigraphy with Technetium-99m-Sestamibi in Suspected Breast Cancer",
abstract = "Our goal was to determine the clinical usefulness of 99mTc-sestamibi to identify breast cancer in patients prior to biopsy. Methods: We studied 66 patients who received 20 mCi 99mTc-sestamibi intravenously. Lateral and anterior planar images were gathered within 30 min of the injection. Only focal increased uptake was interpreted as positive. Confirmatory pathologic diagnoses were obtained within 2 mo. The prevalence of breast cancer in our sample was 54{\%}. Results: We report an overall sensitivity of 83{\%} and specificity of 93{\%} for the diagnosis of breast cancer. In palpable lesions, the sensitivity was of 94{\%} with a specificity of 91{\%}, while in nonpalpable abnormalities the sensitivity was of 64{\%} with a 100{\%} specificity. Six patients with a malignancy had negative scans, four of these lesions were nonpalpable. Only two of 31 patients with benign lesions had an abnormal scan. Conclusion: Mammoscintigraphy with 99mTc-sestamibi has high specificity and adequate sensitivity for the noninvasive diagnosis of breast carcinomas.",
keywords = "Breast cancer, Technetium-99m-sestamibi",
author = "Javier Villanueva-Meyer and Leonard, {M. H.} and E. Briscoe and F. Cesani and Ali, {S. A.} and S. Rhoden and M. Hove and D. Cowan",
year = "1996",
language = "English",
volume = "37",
pages = "926--930",
journal = "Journal of Nuclear Medicine",
issn = "0161-5505",
publisher = "Society of Nuclear Medicine Inc.",
number = "6",

}

TY - JOUR

T1 - Mammoscintigraphy with Technetium-99m-Sestamibi in Suspected Breast Cancer

AU - Villanueva-Meyer, Javier

AU - Leonard, M. H.

AU - Briscoe, E.

AU - Cesani, F.

AU - Ali, S. A.

AU - Rhoden, S.

AU - Hove, M.

AU - Cowan, D.

PY - 1996

Y1 - 1996

N2 - Our goal was to determine the clinical usefulness of 99mTc-sestamibi to identify breast cancer in patients prior to biopsy. Methods: We studied 66 patients who received 20 mCi 99mTc-sestamibi intravenously. Lateral and anterior planar images were gathered within 30 min of the injection. Only focal increased uptake was interpreted as positive. Confirmatory pathologic diagnoses were obtained within 2 mo. The prevalence of breast cancer in our sample was 54%. Results: We report an overall sensitivity of 83% and specificity of 93% for the diagnosis of breast cancer. In palpable lesions, the sensitivity was of 94% with a specificity of 91%, while in nonpalpable abnormalities the sensitivity was of 64% with a 100% specificity. Six patients with a malignancy had negative scans, four of these lesions were nonpalpable. Only two of 31 patients with benign lesions had an abnormal scan. Conclusion: Mammoscintigraphy with 99mTc-sestamibi has high specificity and adequate sensitivity for the noninvasive diagnosis of breast carcinomas.

AB - Our goal was to determine the clinical usefulness of 99mTc-sestamibi to identify breast cancer in patients prior to biopsy. Methods: We studied 66 patients who received 20 mCi 99mTc-sestamibi intravenously. Lateral and anterior planar images were gathered within 30 min of the injection. Only focal increased uptake was interpreted as positive. Confirmatory pathologic diagnoses were obtained within 2 mo. The prevalence of breast cancer in our sample was 54%. Results: We report an overall sensitivity of 83% and specificity of 93% for the diagnosis of breast cancer. In palpable lesions, the sensitivity was of 94% with a specificity of 91%, while in nonpalpable abnormalities the sensitivity was of 64% with a 100% specificity. Six patients with a malignancy had negative scans, four of these lesions were nonpalpable. Only two of 31 patients with benign lesions had an abnormal scan. Conclusion: Mammoscintigraphy with 99mTc-sestamibi has high specificity and adequate sensitivity for the noninvasive diagnosis of breast carcinomas.

KW - Breast cancer

KW - Technetium-99m-sestamibi

UR - http://www.scopus.com/inward/record.url?scp=0030161486&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0030161486&partnerID=8YFLogxK

M3 - Article

VL - 37

SP - 926

EP - 930

JO - Journal of Nuclear Medicine

JF - Journal of Nuclear Medicine

SN - 0161-5505

IS - 6

ER -